Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
Completed · Phase 2
Conditions studied: Non Small Cell Lung Cancer
In brief
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive
Key facts
- Study ID
- NCT02094261
- Run by
- AstraZeneca
- People needed
- 210
- Starts
- 2014-05-20
- Expected to finish
- 2023-11-07
- Last updated by the study team
- 2024-11-06
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — La Jolla, California, United States
- Research Site — Orange, California, United States
- Research Site — New Haven, Connecticut, United States
- Research Site — Norwalk, Connecticut, United States
- Research Site — Indianapolis, Indiana, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Lebanon, New Hampshire, United States
- Research Site — New York, New York, United States
- Research Site — Durham, North Carolina, United States
- Research Site — Edmonton, Alberta, Canada
- Research Site — Ottawa, Ontario, Canada
- Research Site — Toronto, Ontario, Canada
- Research Site — Hong Kong, Hong Kong
- Research Site — Shatin, Hong Kong
- Research Site — Milan, Italy
- Research Site — Milan, Italy
- Research Site — Naples, Italy
- Research Site — Perugia, Italy
- Research Site — Verona, Italy
- Research Site — Akashi-shi, Japan
- Research Site — Chūōku, Japan
- Research Site — Kitaadachi-gun, Japan
- Research Site — Kitakyushu-shi, Japan
- Research Site — Kōtoku, Japan
- Research Site — Nagoya, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.